EGFR and cancer: CLC1b and Dyn1 control the “adaptive” CME of EGFR, as opposed to constitutive CME governed by CLCa/b and Dyn2, promoting EGFR trafficking and signalling, and enhancing the metastatic ability of cancer cells in vivo36 (Figure 1C).